← Leaderboards
Edmund A Rossi
Immunomedics, Inc.
$2,962,708
Attributed
$2,962,708
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.3M · FY2009–11$2.5M$1.9M$1.3M$625K$0
'09
'10
'11
Funding mix
By agency
NIH$2,962,708 · 2
By mechanism
R44$2,828,873 · 1
R43$133,835 · 1
Top collaborators
No co-investigators on record.
Most similar at Immunomedics, Inc.
Same institution · by research overlap
- William John McBride$1,257,246
- William A. Wegener$2,714,853
- Chien Hsing K. Chang$1,347,339
- Thomas M Cardillo$192,688
Others in their field
Top investigators on “S Lymphoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$171,980,034
- Richard L Schilsky · University Of Chicago$120,036,663
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$113,682,224
- Ronald T Mitsuyasu · University Of California Los Angeles$103,553,444
- Monica M Bertagnolli · Strang Cancer Prevention Center$61,393,123
- Charles A Coltman · Southwest Oncology Group$55,198,633
Research focus
S LymphomaSafetyDoseProductionHalf-LifeSiteInterferon Alfa-2aLeadMacaca FascicularisMonoclonal Antibody Cd20Drug FormulationsPublic Health RelevanceB-Cell LymphomasB Lymphoid MalignancyLearningImmunoglobulin GBiochemicalInterferon-AlphaDockingLymphomaBiologicalMonoclonal AntibodiesPrototypeSolid Neoplasm
Grant awards (3)
Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy$2,283,892
R44 · FY2011 · CA · contact PI
Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy$544,981
R44 · FY2010 · CA · contact PI
Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy$133,835
R43 · FY2009 · CA · contact PI